Patel Nirav, Gupta Ankur, Doshi Rajkumar, Kalra Rajat, Bajaj Navkaranbir S, Arora Garima, Arora Pankaj
Division of Cardiovascular Disease, University of Alabama at Birmingham Birmingham, AL (N.P., N.S.B., G.A., P.A.).
Cardiovascular Division, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.G., N.S.B.).
Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e004971. doi: 10.1161/CIRCOUTCOMES.118.004971.
Medicaid expansion among previously uninsured individuals has led to improved healthcare access. However, considerably lower reimbursement rates of Medicaid have raised concerns on the unintended consequence of lower utilization of life-saving therapies and inferior outcomes compared with private insurance. We examined the rates of revascularization and in-hospital mortality among Medicaid beneficiaries versus privately insured individuals hospitalized with ST-segment-elevation myocardial infarction (STEMI).
We queried the National Inpatient Sample from 2012 to 2015 for STEMI hospitalizations with Medicaid or private insurance as primary payer. Hospitalizations with the following criteria were excluded: (1) age <18 or ≥65 years, (2) transfer to another acute care facility, and (3) left against medical advice. Outcomes were compared in propensity score-matched cohort based on demographics, socioeconomic status (income based), clinical comorbidities, including drug and alcohol use, STEMI acuity (cardiac arrest and cardiogenic shock), and hospital characteristics. A total of 42 645 and 171 545 STEMI hospitalizations were identified as having Medicaid and private insurance, respectively. In unadjusted analyses, Medicaid beneficiaries with STEMI had lower rates of coronary revascularization (88.9% versus 92.3%; odds ratio, 0.67; 95% CI, 0.65-0.70) and higher rates of in-hospital mortality (4.9% versus 2.8%; odds ratio, 1.81; 95% CI, 1.72-1.91) compared with privately insured individuals ( P<0.001 for both). In propensity-matched cohort of 40 870 hospitalizations per group, similar results for lower rates of revascularization (89.1% versus 91.1%; odds ratio, 0.80; 95% CI, 0.76-0.84) and higher in-hospital mortality (4.9% versus 3.7%; odds ratio, 1.35; 95% CI, 1.26-1.45) were observed in Medicaid compared with private insurance, despite extensive matching ( P<0.001 for both).
Medicaid beneficiaries with STEMI had lower rates of revascularization, although small absolute difference, and higher in-hospital mortality compared with privately insured individuals. Further studies are needed to identify and understand the variation in STEMI outcomes by insurance status.
先前未参保人群的医疗补助计划(Medicaid)扩大导致医疗服务可及性得到改善。然而,Medicaid的报销率显著低于私人保险,这引发了人们对其可能导致与私人保险相比挽救生命疗法的使用率降低以及治疗效果较差这一意外后果的担忧。我们研究了因ST段抬高型心肌梗死(STEMI)住院的Medicaid受益人与私人保险参保者的血管重建率和住院死亡率。
我们查询了2012年至2015年全国住院患者样本中以Medicaid或私人保险作为主要支付方的STEMI住院病例。排除符合以下标准的住院病例:(1)年龄<18岁或≥65岁;(2)转至另一家急性护理机构;(3)违反医嘱擅自离院。基于人口统计学、社会经济状况(收入)、临床合并症(包括药物和酒精使用情况)、STEMI严重程度(心脏骤停和心源性休克)以及医院特征,在倾向得分匹配队列中比较结果。共确定42645例和171545例STEMI住院病例分别有Medicaid和私人保险。在未经调整的分析中,与私人保险参保者相比,患有STEMI的Medicaid受益人冠状动脉血管重建率较低(88.9%对92.3%;优势比,0.67;95%CI,0.65 - 0.70),住院死亡率较高(4.9%对2.8%;优势比,1.81;95%CI,1.72 - 1.91)(两者P<0.001)。在每组40870例住院病例的倾向匹配队列中,与私人保险相比,Medicaid的血管重建率较低(89.1%对91.1%;优势比,0.80;95%CI,0.76 - 0.84)和住院死亡率较高(4.9%对3.7%;优势比,1.35;95%CI,1.26 - 1.45)的情况依然存在,尽管进行了广泛匹配(两者P<0.001)。
患有STEMI的Medicaid受益人血管重建率较低,尽管绝对差异较小,且与私人保险参保者相比住院死亡率较高。需要进一步研究以确定并理解不同保险状况下STEMI治疗结果的差异。